JP2006528942A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528942A5
JP2006528942A5 JP2006529742A JP2006529742A JP2006528942A5 JP 2006528942 A5 JP2006528942 A5 JP 2006528942A5 JP 2006529742 A JP2006529742 A JP 2006529742A JP 2006529742 A JP2006529742 A JP 2006529742A JP 2006528942 A5 JP2006528942 A5 JP 2006528942A5
Authority
JP
Japan
Prior art keywords
alkyl
chloro
indazole
alkylene
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006529742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528942A (ja
JP4709763B2 (ja
Filing date
Publication date
Priority claimed from EP03011303A external-priority patent/EP1479675A1/en
Application filed filed Critical
Publication of JP2006528942A publication Critical patent/JP2006528942A/ja
Publication of JP2006528942A5 publication Critical patent/JP2006528942A5/ja
Application granted granted Critical
Publication of JP4709763B2 publication Critical patent/JP4709763B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006529742A 2003-05-19 2004-05-05 第Xa因子阻害剤としてのインダゾール誘導体 Expired - Fee Related JP4709763B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03011303.9 2003-05-19
EP03011303A EP1479675A1 (en) 2003-05-19 2003-05-19 Indazole-derivatives as factor Xa inhibitors
PCT/EP2004/004753 WO2004101556A1 (en) 2003-05-19 2004-05-05 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (3)

Publication Number Publication Date
JP2006528942A JP2006528942A (ja) 2006-12-28
JP2006528942A5 true JP2006528942A5 (enExample) 2007-05-17
JP4709763B2 JP4709763B2 (ja) 2011-06-22

Family

ID=33040950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529742A Expired - Fee Related JP4709763B2 (ja) 2003-05-19 2004-05-05 第Xa因子阻害剤としてのインダゾール誘導体

Country Status (13)

Country Link
US (1) US7365088B2 (enExample)
EP (2) EP1479675A1 (enExample)
JP (1) JP4709763B2 (enExample)
AT (1) ATE429432T1 (enExample)
AU (1) AU2004238499A1 (enExample)
BR (1) BRPI0410430A (enExample)
CA (1) CA2528220A1 (enExample)
CL (1) CL2004001080A1 (enExample)
DE (1) DE602004020761D1 (enExample)
MX (1) MXPA05012346A (enExample)
PE (1) PE20050153A1 (enExample)
TW (1) TW200510400A (enExample)
WO (1) WO2004101556A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581503A4 (en) * 2002-11-08 2007-07-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
AU2004271978B2 (en) * 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
CA2563617A1 (en) * 2004-04-20 2005-11-03 Rnd Pharmaceuticals Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CN101821260B (zh) 2007-08-14 2013-07-31 康塞特医药品有限公司 取代的噁唑烷酮衍生物
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
EP2705028B1 (en) 2011-05-06 2019-08-21 Egis Gyógyszergyár Zrt. Process for the preparation of a rivaroxaban and intermediates formed in said process
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CN109456205B (zh) * 2018-12-17 2021-09-21 石河子大学 以取代喹啉或异喹啉酰肼吡啶-n-氧化物为配体的水相体系中的n-芳基化方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
CA2186497C (en) 1994-04-26 2008-06-17 Fahad Al-Obeidi Factor xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
WO2000039131A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
HUP0203375A3 (en) 1999-07-28 2005-03-29 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
DE10014645A1 (de) 2000-03-24 2001-09-27 Merck Patent Gmbh Substituierte Biphenylderivate
CA2409762A1 (en) * 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US7157487B2 (en) * 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
EP1571154A1 (en) 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors

Similar Documents

Publication Publication Date Title
JP2006528942A5 (enExample)
JP2006511608A5 (enExample)
JP2006528940A5 (enExample)
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
US7910606B2 (en) Pyrazole-derivatives as factor Xa inhibitors
CA2467374A1 (en) Indole-2-carboxamides as factor xa inhibitors
JP4676960B2 (ja) 第Xa因子阻害剤としてのインドール誘導体
JP4709763B2 (ja) 第Xa因子阻害剤としてのインダゾール誘導体
JP2011518836A5 (enExample)
JP2006500348A5 (enExample)
JP2005514365A5 (enExample)
KR20060136457A (ko) 인자 Xa 억제제로서의 피롤-유도체
JP2011503194A5 (enExample)
HRP20020221A2 (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
JP2006512412A5 (ja) 神経系の疾患の治療用のベンズアゼピン誘導体
HRP20120225T1 (hr) Novi heterociklični spojevi kao mglu5 antagonisti
WO2006073361A1 (en) Novel pyridine compounds
JP2006514093A5 (enExample)
US20050009829A1 (en) Benzimidazole-derivatives as factor Xa inhibitors
JP2006528213A5 (enExample)
CA2526082A1 (en) Triazole-derivatives as factor xa inhibitors
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
JP2006528214A5 (enExample)
RU2005139557A (ru) Азаиндольные производные в качестве ингибиторов фактора ха